MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, APVO had $11,651K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$11,651K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,549 -12,612
Stock-based compensation
77 17
Depreciation and amortization
49 110
Prepaid expenses and other current assets
-83 -274
Operating lease right-of-use asset
148 278
Accounts payable, accrued compensation and other liabilities
724 -1,315
Long-term operating lease liability
-220 -420
Net cash used in operating activities
-6,688 -13,668
Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs
-14,364
Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs
32,703 -
Net cash used in financing activities
18,339 14,364
Increase (decrease) in cash and cash equivalents
11,651 696
Cash and cash equivalents at beginning of period
8,714 -
Cash and cash equivalents at end of period
21,061 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc. (APVO)